IDOV-Immune for Advanced Solid Tumors
A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors
Sponsor: ViroMissile, Inc.
A PHASE1 clinical study on Adrenal Gland Tumors and Bladder Cancer, this trial is actively recruiting participants. The trial is conducted by ViroMissile, Inc. and has accumulated 8 data snapshots since 2025. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Mar 2026 — Present [monthly]
Recruiting PHASE1
-
Feb 2026 — Mar 2026 [monthly]
Recruiting PHASE1
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE1
-
Dec 2025 — Jan 2026 [monthly]
Recruiting PHASE1
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE1
▶ Show 3 earlier versions
-
Oct 2025 — Nov 2025 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Sep 2025 — Oct 2025 [monthly]
Not Yet Recruiting PHASE1
-
May 2025 — Sep 2025 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- ViroMissile, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .